Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - oxaliplatin, quantity: 50 mg - injection, powder for - excipient ingredients: mannitol - in combination with fluorouracil and folinic acid: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; and treatment of advanced colorectal cancer.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - aciclovir, quantity: 200 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and adminsitration" sections of the approved product information provided as attachment 1.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - aciclovir, quantity: 400 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and administration" sections of the approved product information provided as attachment 1.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - aciclovir, quantity: 200 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and adminsitration" sections of the approved product information provided as attachment 1.

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - triclopyr present as the butoxyethyl ester; diethylene glycol monomethyl ether - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l; diethylene glycol monomethyl ether solvent other 226.0 g/l - herbicide

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

oasis trading - levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz), lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), econazole nitrate (unii: h438wyn10e) (econazole - unii:6z1y2v4a7m) - when left untreated, the symptoms can be painful, unsightly, and make walking difficult. here are the most common symptoms: itching or burning between your toes or on the soles of your feet white, wet-looking skin in between your toes flaky skin or small tears (fissures) on feet or in-between toes red rash between the toes blisters or ulcers on the skin on top of foot broken blisters, causing pain and swelling thick, dry, scaly skin on the bottom and sides of feet ■first wash and dry your feet thoroughly ■ adults and children 2 years of age and older: apply to the affected area no more than 3 to 4 times daily ■ children under 2 years of age: consult a doctor

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 832.5 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; sodium starch glycollate type a; microcrystalline cellulose; purified talc; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 555 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; maize starch; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

nrc nutrition pty ltd - passiflora incarnata, quantity: 25 mg (equivalent: passiflora incarnata, qty 1.25 g); matricaria chamomilla, quantity: 112.5 mg (equivalent: matricaria chamomilla, qty 900 mg); withania somnifera, quantity: 112.5 mg (equivalent: withania somnifera, qty 2.25 g); lavender oil, quantity: 40 mg; crocus sativus, quantity: 2.997 mg (equivalent: crocus sativus, qty 9.99 mg) - capsule, hard - excipient ingredients: calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; ascorbyl palmitate; microcrystalline cellulose; maltodextrin; hypromellose; potable water; dextrin - traditionally used in western herbal medicine to adaptogen/help body adapt to stress ; traditionally used in western herbal medicine to help maintain/support emotional wellbeing ; traditionally used in western herbal medicine to soothe/calm nerves ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild anxiety ; traditionally used in western herbal medicine to calmative/nervous system relaxant ; traditionally used in western herbal medicine to nervine/support nervous system ; traditionally used in western herbal medicine to decrease/reduce/relieve sleeplessness ; traditionally used in western herbal medicine to decrease/reduce/relieve disturbed/restless sleep ; traditionally used in western herbal medicine to enhance/promote/increase healthy sleep patterns ; traditionally used in western herbal medicine to maintain/support healthy sleeping patterns

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

nrc nutrition pty ltd - salvia officinalis, quantity: 90 mg (equivalent: salvia officinalis, qty 900 mg; equivalent: thujone, qty 3.6 mg); valeriana officinalis, quantity: 175 mg (equivalent: valeriana officinalis, qty 1.75 g); humulus lupulus, quantity: 94.67 mg (equivalent: humulus lupulus, qty 710 mg); ziziphus jujuba var. spinosa, quantity: 66.67 mg (equivalent: ziziphus jujuba var. spinosa, qty 2 g) - capsule, hard - excipient ingredients: calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; microcrystalline cellulose; maltodextrin; ascorbyl palmitate; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - traditionally used in western herbal medicine to soporific/induces sleep ; traditionally used in western herbal medicine to decrease/reduce time to fall asleep ; traditionally used in western herbal medicine to decrease/reduce/relieve disturbed/restless sleep ; traditionally used in western herbal medicine to enhance/promote/increase healthy sleep patterns ; traditionally used in western herbal medicine to helps decrease/reduce/relieve night sweats associated with menopause ; maintain/support oestrogen hormone levels ; traditionally used in western herbal medicine to maintain/support healthy reproductive hormones